| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-08-08 | AZD9773 (CytoFab™) | sepsis septic shock |
2b | BTG (UK) AstraZeneca (UK) | Infectious diseases |
| 2012-08-08 | arasertaconazole nitrate | vulvovaginal candidiasis (VVC) | 3 | Ferrer (Spain) | Infectious diseases |
| 2012-08-07 | PLX cells (PLacental eXpanded cells) | regeneration of injured gluteal musculature following total hip replacement | 1-2 | Pluristem Therapeutics (Israel) | Regenerative medicine - Muscular diseases |
| 2012-08-06 | talactoferrin alfa (talactoferrin) | patients with non-small cell lung cancer (NSCLC) whose disease had progressed following two or more prior treatment regimens. | 3 | Agennix (Germany) | Cancer - Oncology |
| 2012-08-06 | bapineuzumab | Alzheimer's disease | 3 | Pfizer (USA - NY) Janssen AI (USA) Elan (Ireland) | Neurodegenerative diseases |
| 2012-08-06 | NVB302 | Clostridium difficile infection | 1 | Novacta Biosystems (UK) | Infectious diseases |
| 2012-07-29 | IMA901 | renal cell carcinoma | immatics biotechnologies (Germany) the University of Tübingen (Germany) | Cancer - Oncology | |
| 2012-07-27 | RoActemra® (tocilizumab) | rheumatoid arthritis | 3 | Roche (Switzerland) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2012-07-25 | JX594/TG6006 (Pexa-Vec) | hepatocellular carcinoma | 2b | Transgene (France) Jennerex (USA) | Cancer - Oncology |
| 2012-07-24 | Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) | advanced prostate cancer |
3 | Debiopharm (Switzerland) | Cancer - Oncology |
| 2012-07-23 | Tarceva® (erlotinib) | unresectable hepatocellular carcinoma |
3 | Bayer Health care (Germany) Onyx Pharmaceuticals (USA) Astellas Pharma (Japan) | Cancer - Oncology |
| 2012-07-23 | bapineuzumab | mild-to-moderate Alzheimer’s disease in patients who carry the ApoE4 (apolipoprotein E epsilon 4) genotype |
3 | Pfizer (USA - NY) Janssen AI Elan (Ireland) | Neurodegenerative diseases |
| 2012-07-20 | SAR236553/REGN727 | - patients with heFH who are inadequately controlled by current lipid-modifying therapy - high cardiovascular risk patients with primary hypercholesterolemia |
3 | Sanofi (France) Regeneron Pharmaceuticals (USA) | Cardiovascular diseases - Metabolic diseases |
| 2012-07-18 | herpes zoster vaccine (HZ/su) containing Agenus' QS-21 Stimulon®1 adjuvant | prevention of shingles (herpes zoster) in immunocompromised patients |
3 | GSK (UK) | Infectious diseases |
| 2012-07-16 | recombinant human lactoferrin | Pharming (The Netherlands) | |||
| 2012-07-16 | 2B3-201 (brain-targeted liposomal methylprednisolone) | neuroinflammation | to-BBB (The Netherlands) | Inflammatory diseases - Neurodegenerative diseases | |
| 2012-07-12 | Kogenate® Bayer (octocog alfa) | hemophilia A |
3 | Bayer Healthcare (Germany) | Hematological diseases - Genetic diseases |
| 2012-07-11 | dolutegravir-based regimen | HIV-Aids | 3 | Shionogi-ViiV Healthcare (Japan - UK - USA) | Infectious diseases |
| 2012-07-11 | Avastin® (bevacuzimab) | wet age-related macular degeneration (AMD) | The University of Nottingham (UK) | Ophtalmological diseases | |
| 2012-07-11 | albiglutide | type 2 diabetes | 3 | GSK (UK) | Metabolic diseases |
